• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    11/14/24 3:05:15 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGNE alert in real time by email
    SC 13G/A 1 cormorant-ngne093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Neurogene Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    64135M105

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  64135M105
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Cormorant Asset Management, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    107,344
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    107,344
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    107,344
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.83%
    12
    TYPE OF REPORTING PERSON
     
    IA

     
     


     

    CUSIP No.  64135M105
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Bihua Chen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    107,344
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    107,344
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    107,344
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.83%
    12
    TYPE OF REPORTING PERSON
     
    IN
     
     


     

     

    CUSIP No. 64135M105
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Neurogene Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    535 W 24th St., 5th Floor

    New York, NY 10011

    Item 2.(a) Names of Person Filing:

    Cormorant Asset Management, LP

    Bihua Chen

    This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 2.(b) Address of Principal Business Office:

    200 Clarendon Street, 52nd Floor

    Boston, MA 02116

     

    Item 2.(c) Citizenship:

    Cormorant Asset Management, LP - Delaware

    Bihua Chen - United States

     

    Item 2.(d) Title of Class of Securities

    Common Stock (the "Shares")

     

    Item 2.(e) CUSIP No.:

    64135M105

     

    CUSIP No.  64135M105
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 64135M105
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned

    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    (b) Percent of class

    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    (ii) Shared power to vote or to direct the vote

    (iii) Sole power to dispose or to direct the disposition of

    (iv) Shared power to dispose or to direct the disposition of

    The information set forth in Rows 5 through 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission on August 9, 2024, that there were 12,993,613 shares of voting Common Stock of the Issuer outstanding as of August 5, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a -11.

     

     
    CUSIP No. 64135M105
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           

     

     
    CUSIP No. 64135M105
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           
    Get the next $NGNE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NGNE

    DatePrice TargetRatingAnalyst
    6/17/2025$50.00Buy
    Craig Hallum
    5/16/2025$24.00Outperform → Neutral
    Robert W. Baird
    6/27/2024$65.00Outperform
    BMO Capital Markets
    6/11/2024$54.00Outperform
    Robert W. Baird
    4/29/2024$46.00Outperform
    Leerink Partners
    3/21/2024$61.00Outperform
    William Blair
    More analyst ratings

    $NGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baffi Robert

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:42 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Robert Keith

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:13 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Palekar Rohan

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:06:44 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

    Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollment New preclinical data at ESGCT Congress highlight NGN-401 best-in-class potential and add to body of evidence that ICV administration is superior to IT-L in reaching key brain regions underlying Rett syndrome As previously reported, the first four participants in the NGN-401 Phase 1/2 trial gained 23 developmental milestones/skills, representing multi-domain improvement that requires transduction of key brain regions and nervous system The preclinical data also provide evidence-based confirmation that ICV and IT-L administration result in comparable peripheral organ transduction, showing n

    10/9/25 7:00:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's website under events, where a replay of the event will also be available for a limited time. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to imp

    10/8/25 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 9,390 shares of the Company's common stock to four new employees (the "Inducement Grants") on October 1, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance w

    10/3/25 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    SEC Filings

    View All

    Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Neurogene Inc. (0001404644) (Filer)

    10/9/25 7:01:21 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Neurogene Inc.

    SCHEDULE 13G/A - Neurogene Inc. (0001404644) (Subject)

    8/14/25 4:27:25 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Neurogene Inc.

    424B5 - Neurogene Inc. (0001404644) (Filer)

    8/11/25 4:48:06 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Neurogene with a new price target

    Craig Hallum initiated coverage of Neurogene with a rating of Buy and set a new price target of $50.00

    6/17/25 8:10:28 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Neurogene from Outperform to Neutral and set a new price target of $24.00

    5/16/25 8:03:18 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets initiated coverage on Neurogene with a new price target

    BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00

    6/27/24 7:50:19 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Samsara Biocapital Gp, Llc bought $1,259,623 worth of shares (48,770 units at $25.83) (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/27/24 4:39:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Cvijic Christine Mikail bought $491,400 worth of shares (24,000 units at $20.48), increasing direct ownership by 45% to 76,844 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mcminn Rachel bought $969,000 worth of shares (47,500 units at $20.40), increasing direct ownership by 4% to 1,297,859 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:04 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Leadership Updates

    Live Leadership Updates

    View All

    Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha

    11/18/24 6:45:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

    Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom

    3/18/24 4:14:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Financials

    Live finance-specific insights

    View All

    Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

    11/11/24 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

    Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking

    10/21/24 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurogene Inc.

    SC 13G - Neurogene Inc. (0001404644) (Subject)

    12/11/24 4:05:09 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/27/24 4:25:10 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/14/24 4:53:08 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care